| For: | He WM, Li WS. Investigating radiotherapy’s impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab. World J Gastrointest Oncol 2025; 17(12): 110621 [PMID: 41480214 DOI: 10.4251/wjgo.v17.i12.110621] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v17/i12/110621.htm |
| Number | Citing Articles |
| 1 |
Min Li, Qian Ban, Dahai Liu, Bingang Li, Jintang Xu, Jiaqi Geng, Dakun Chen, Wenqiao Hui. A CS•CBE
System Targeting β-Catenin:
Exploring Additional Inhibition Targets for Colon Cancer Proliferation. ACS Omega 2026; doi: 10.1021/acsomega.6c04206
|
| 2 |
Kenji Makita, Masaki Nakamura, Yuichi Hiroshima, Hidenari Hirata, Masashi Wakabayashi, Saori Mishima, Akihito Kawazoe, Satoshi Saito, Sadamoto Zenda. Gastrointestinal perforation associated with bevacizumab and palliative radiotherapy. International Journal of Clinical Oncology 2026; doi: 10.1007/s10147-026-03191-z
|
| 3 |
Yan Xu, Xiao-Bing Huang, Yong-Gang He. Radiotherapy combined with bevacizumab in gastrointestinal cancers: Balancing efficacy against the risk of intestinal perforation. World Journal of Radiology 2026; 18(1): 116084 doi: 10.4329/wjr.v18.i1.116084
|